

Engineering novel lentiviral vectors in labelling tumour cells and oncogenic proteins

Table S1. DNA sequences of primers used in amplification of vectors and inserts.

Primer name	PCR product	Sequence (5'-3')	Length	Tm (~) *	GC content
Forward-1	Empty pLVX vector	ACA AGG GCG GCA ACA GCG TG	20 bp	65°C	65%
Reverse-1	Empty pLVX vector	TTT AAA CTC GAG GGT GGC GAC CGG TAG ATC CT	32 bp	69°C	53%
Forward-2	E2-Crimson gene	AAA TTT CTC GAG ATG GAT AGC ACT GAG AAC GTC	33 bp	63°C	42%
Reverse-2	E2-Crimson gene	TTT AAA GAA TTC CTA CTG GAA CAG GTG GTG GCG	33 bp	65°C	46%
Forward-3	ZsYellow gene	AAA TTT CTC GAG ATG GCT CAT TCA AAG CAC GGT	33 bp	66°C	42%
Reverse-3	ZsYellow gene	TTT AAA GAA TTC TCA GGC CAA GGC AGA AGG GAA	33 bp	65°C	42%
Forward-4	HA-tagged EPHA3 gene	AAA TTT CTC GAG ATG GAT TGT CAG CTC TCC ATC CTC CTC CTT CTC AGC TGC TCT GTT CTC GAC AGC TTC GGG TAC CCA TAC GAT GTT CCA GAT TAC GCT GAA CTG ATT CCG CAG	114 bp	95°C	50%
Reverse-4	HA-tagged EPHA3 gene	TTT AAA GAA TTC TTA CAC GGG AAC TGG GCC	30 bp	63°C	43%

Extra space for restriction enzymes

XhoI restriction site (C▼TCGAG)

EcoRI restriction site (G▼AATTC)

START codon (ATG)

Signal peptide

HA-tag

* Tm values were calculated by using ApE (A Plasmid Editor) software.

Table S2. DNA sequence of pLVX-AmCyan1-C1 lentiviral expression plasmid. Functional regions are highlighted with different colours. Note the binding sites of Forward-1 (Line-28) and Reverse-1 (Line-23) primers.

ttggaagggttaattcactccaaagaagacaagatacttgatctgtggatctaccacacacaaggctacttccctgattagcagaactacacaccagggtccagggtcagataccactgacct
 ttggatgggtgtacaaagctagctaccagttgagccagataaggtagaagaggccaataaaggagagaacaccagctgttacaccctgtgagcctgcatgggatggatgacccggagagagaa
 ggttagagtgagggtttgacagccgcttagcattcatcacgtggcccgagagctgcatccggagtacttcaagaactgctgatatcgagctgtctacaagggaacttccgctggggactttcca
 gggaggcgtggcctgggaggactgggagtgccgagccctcagatctctgcatataagcagctgcttttctgctgactgggtctctctggttagaccagatctgagcctgggagctctctggct
 aactagggaaccactgcttaagcctcaataaagcttgccttgagtcttcaagtagtgtgtgcccgtctgtgtgtgactctggttaactagagatccctcagacccttttagtcagtgtggaaatct
 ctgagctgtggcgccgaacagggaacttgaagcgaagggaaaccagagagctctctcagcagagactcggctgtgtaagcgcgcacggcaagaggcgaggggcgggcgactggtga
 gtacgccaataattttgactagcggaggctagaaggagagagatgggtgagagagcgtcagattaaagggggagaattagatcgcatgggaaaaaattcggttaaggccagggggaa
 agaaaaataataaataaataatagatgtggcaagcagggagctagaacgattcgagttaatctggcctgttagaatacagaaggctgtagacaatactgggacagctacaaccatc
 ccttcagacaggatcagaagaacttagatcattatataatcagtagcaaccctctattgtgtgcatcaaggatagagataaaagacaccaaggaagcttagacaagatagaggaaagagcaa
 aacaaaagtaagaccaccgcacagcaagcgccggcgtgactctcagacctggaggagagatatagggacaattggagaagtgaattatataaataaagtagtaaaaaattgaacca
 ttaggatgtagccccaaggcaagagaagagtggtgcagagagaaaaagagcagtggaataggagctttgttcttgggttcttgggagcagcaggaagcactatggcgagcgt
 caatgacgctgacggtacagggcagacaattattgtctgtatagtcagcagcagacaatttctgagggtattgaggcgcaacagcatctgttgaactcagacttggggcatcaagca
 gctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggaatttgggtgtctctggaactcatttgaccactgctgtgcttggatgtagtggagtaataa
 atctctggaacagatttgaatcacagacctggatggagtgaggagagaaataaataacagcttaatacactccttaattgaagaatcgaaaaccagcaagaaagaatgaacaa
 gaattattggaattagataaattggcaagtttgtgaattggttaacatacaaaattggctgtggtatataaaattattcataatgatagtaggaggcttggtaggttaagaatagttttgctgta
 cttctatagtgaaatagagttaggcaggatattcaccattatcgttccagaccaccccaaccccgaggggaccgacaggccgaaggaatagaagaagaaggtggagagagagacag
 agacagatccattcgattagtgacggatctgcagcgtatcgctttaaagaaaagggggattggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaaat
 aaagaattacaaaaacaattacaaaaattcaaaattttcggtttattacaggagcagcagagatccagtttatcgataagcttgggagttccgctgtacataacttacggtaaatggccgcctg
 gctgacgcccacacaccccgccattgacgtcaataatgacgtatgttccatagtaacgcaatagggaacttccattgacgtcaatgggtggagtattacggtaaaactgccacttggcagt
 acatcaagtgtatcatatgccagtagcggccttattgacgtcaatgacggtaaatggccgcctggcattatgccagtagatgacattatgggacttctacttggcagtacatctacgtattagt
 catcgctattaccatgggtgatcggttttggcagtagatcaatggcggtgtagcggttactcacgggatttcaagctccacccattgacgtcaatgggagttgttttggcaccaaaatc
 aacgggactttccaaatgtcgtgaactcggccctttagcgcgaatggcggttaggcgtgtacgggtgggaggtctatataagcagagctcgttttagtgaaccgtcagatcgctggagagc
 ccatccacgctgttttgacctcatagaagacaccgactctactagaggatctacgggtgcgcccatggcctgtccaacaagttcatcggcagcagatgaagatgacctaccatgagcggc
 tgcgtgaacggccacttaccgtgaaggcgaggcgagggcagcggaagcctcagagggaaccagacctccactcaaggtgacatggccaacggcgggcccttgccttctccttcagc

atctctgtccaccgtgttcatgtacggcaaccgctgttccaccgctacccaccagcatgccgactacttcaagcaggccttccccacggcatgtctacgagagaaccttccactacgaggacg
gcggtgtggccaccgcccagctgggagatcagcctgaagggcaactgtctcagcacaagtcacacttccacggtgtaacttccccgcgcagggccccgtgatggccaagaagaccaccggc
tgggacctctctcagaagatgacctgtgtcgacggcatcttgaagggcgacgtgaccttctctgatgtcagggcgcggaactacagatgccagttccacacctctacaagacca
agaagccccgtgacctgcccccaaccacgtggtggagcaccgcatcgccagaaccgacctggacaagggcggaacagcgtgcagctgaccgagcagccgtggccacatcacctccgt
gggtcccttctccgactcagatctcagctcaagcttgaattctcagctcgacgggtaccgccccgggacccggatctagataactgatcataatttaccgggtaggggaggcgctt
tcccaaggcagctgtgagcatgcgttttagcagccccgtggcacttggcgctacacaagtggcctctggcctcgacacattccacatccaccgtaggcgccaaccggctcgttcttgggtg
gccccctcgccaccttctactctccccctagtcaggaagtcccccccgccccgcagctcgctgtcagcagcgtgacaaatggaagtagcacgtctcactagtctgtcagatggacagca
ccgtgagcaatggaagcgggtaggccttggggcagcggccaatagcagcttctctctcgttcttgggtcagaggctgggaaggggtgggtccggggcggggtcaggggggggt
cagggggcgggggcgccccgaaggtctccggagggccccgcattctgcacgttcaaaagcgacgtctgcgcgtgttctctctctctcatctccgggcttctcagctgcagcccaagctt
accatgaccgagtagaagcccaagggtgcctcgcaccccgacgacgtccccaggggcgtacgcacctcgcgcgcgttcgcgactaccccgccacgcgcacacacgtctgacccgac
cgccacatcgagcgggtaccgagctgcaagaactcttctcagcgctggtgggtcgacatcggaaggtgtgggtcgcgacgacggcgccggtgggtgctggaccacgcgggaga
gctgcaagcggggggcggtgttcgcgagatcgccccgcagtcggcgagttgagcgggtccccggtggcgcgacgcaacagatggaaggtccttggcgccgacccggccaaggagc
ccgctgtgttctggccaccgtcggtctcgcggaccaccaggggcaagggtctggcgacgcgcgtctgtctccccggagtgaggcgccgagcgcgcgggggtgcccccttctgga
gacctccgcgccccgcaacctccccctctacgagcgtcggttccacgtcaccgacgtcgaggtgccccgaagaccgacgacctgtgcatgaccgcaagccccggtgctgaaccggt
ctggaacaatcaacctctggattacaaaattgtgaagattgactggtattcttaactatgttgccttttacgctatgttgatacgtgctttaatgcctttgtatcatgtattgttcccgatggctt
tcaatttctctctgtataaatctgtgtgtctctttagaggagttgtggccggtgtcagggcaacgtggcggtgtgtcactgtgttgcagcgaacccccactggttggggcattgccacc
acctgtcagctcttctccggacttctccttccccctccctattgcccagcggaactcatcgccgctgcttcccgtctgtgacaggggctcggtgttgggactgacaattccgtggtgtgtg
tcgggggaagctgacgtcttctatgggtgtcgcctgtgttgcacctggattctgcgcgggacgtctctgtcactgctccctcggccctcaatccagcggaccttcttcccgcggtctgtcgcg
gctctgcggccttctcgcgtcttgccttcgcctcagacgagtcggatctcccttggcgccctccccgcttgaattaattctgcagctcgagacctagaaaaacatggagcaatcacaagtag
caatacagcagctaccaatgtgattgtgctgtgctagaagcacaagaggaggagggtgggttttccagtcacacctcaggtaccttgaagaccaatgacttacaaggcagctgtagatctta
ggcactttttaaagaaaagaggggactggaagggctaattcactcccaacgaagacaagatatcttctgtgtggtatccacacacaaggctacttccctgattagcagaactacacaccag
ggccaggggtcagatatccactgaccttggatgtgtctacaagctagtagcaggttagccagataaggtagaagaggccaataaaggagagaacaccagcttgttacacctgtgagcctgc
atgggatggatgacccggagagagaagtgttagagtgagggtttgacagccgctagcatttcatcacgtggcccgagagctgcatccggagtagtctcaagaactgctgatatcgactgtcta
caagggacttctcgtggggacttccagggagcggtggcctggcgggactggggagtggtcgagccctcagatctgcatataagcagctgcttttgcctgtactgggtctctgtgtagac
cagatctgagctgggagctctctggtaactagggaaacctgtctaagcctaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgtgtgtgactctggttaactagagatccct
cagaccttttagtcagtggtgaaatctctagcagtagtattcatgtatcttattatcagtagttataaactgcaaagaaatgaatatcagagagtgagaggccttgacattgctagcgttttacc
gtgcaccttagctagagcttggcgtaatcatggtcatagctgttctctgtgtgaaattgttatccgctcacaattccacacacatcagagccggaagcataaagtgtaaagcctgggggtgccta
gagtgagctaaatcacaatttgcgttgcgtcactgccccgttccagtcgggaaacctgtcgtgacagctgcattaatgaatcgccaacgcgcggggagaggcggttgcgtattgggcgt
cttccgttctcgtcactgactcgtcgtcgtcgttgcgtcggcgagcgggtatcagctcactcaaaagcggtaatacaggttatccacagaatcaggggataacgcaggaaagaacatg
tgagcaaaaggccagcaaaaggccaggaacgttaaaaggccggttgcgtgctgttttccataggtccgccccctgacgagcatcaaaaaatcgacgctcaagtcagaggtggcgaaa
ccccgacaggactataaagataaccagggttccccctggaagctccctcgtgcgtctcctgttccgacctgcccgttaccggatacgttccgcttctcccttcgggaagcgtggcgcttctcat
agctcagctgttaggtatctcagttcgggttaggtcgttgcctcaagctgggtgtgtgcagaaacccccgttcagcccagcgtcgcttctccggttaactatcgttctgagtcacacccggt
aagacacgacttatcgccactggcagcagccactggttaacaggattagcagagcaggtatgttagcggtgtacagagttctgaagtgtgtggcctaactacggctacactagaagaacagt
atttggtatctgcgtcgtgtaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaaacacccgctggttagcggtgtgtttttgttgaagcagcagattacgcgcaga
aaaaaaggatctcaagaagatctttagcttcttccaggggtgtgacgtcagtggaacgaaactcaggttaagggaatttggatcatgagattacaaaaagatcttccactagatcctttaa
taaaaaatgaagtttaaatcaatctaaagtatatatagtaaacttggctgacagttaaccaatgttaatcagtgaggcacctatctcagcgtatgtctatcttcttcatcatagttgctgactcccc
gtcgtgtagataaactacgatacgggagggttaccatctggccccagtgctcaatgataccgcgagaccacgctcaccggctccagatttatcagaataaaccagccagccggaaggcg
agcgcagaagtgtctcgaactttatccgctccatccagcttataattgttgcgggaagctagagtaagtagttcgccagttatagtttgcgaacgttgttgcattgtctacaggcatctgtg
gtgtcacgctcgtctgttggatgtgcttcatcagctccggttccaacgatcaaggcgagttacatgatccccatgttgtgcaaaaaagcgggttagctcttccgtcctccgatcgtgtcagaagt
aagttggccgagtgattatcactcatggttatggcagcactgcataattcttactgtcatgccatccgtaagatgcttttctgtactggtgagtagtactcaaccaagtcattctgagaatagtgtatgc
ggcgaccgagttgtcttgcggcgctcaatacgggataataccgcgccacatagcagaactttaaagtgtcatcattggaaaacgttcttccggggcgaaaacttcaaggatcttaccgctgt
tgagatccagttcgatgtaacccactcgtgacccaactgatcttcagcatcttcttaccagcgttcttgggtgagcaaaaacaggaaggcaaaatccgcaaaaagggaataaggcg
acacggaagtgtgaatactcactcttcttcaatattatgaagcatttatcagggttattgtctcatgagcggatacatattgaatgtatttagaaaaataaacaatagggttccgcgcac
atttccccgaaaagtgccactgacgtcgacggatcgggagatcaactgtttattgcagcttataatggttacaaataaagcaatagcatcacaatttcacaaataaagcattttttcactgcatc
tagttgtgtgttgcacaaactcatcaatgtatcttatcatgtctggatcaactggataactcaagctaaccacaaatcatcccaactccccaccataccctattaccactgcaattacctgtgtgtcat
ttactctaaacctgtgattcctctgaattatttcattttaagaaattgtattgttaaatagtactacaacttagtagt

Functional DNA region	Line number	Base number
5' LTR	L1-L6	1-635
PBS (primer binding site)	L6	636-653
Ψ (*\packaging signal)	L7	685-822
RRE (Rev-response element)	L11-L13	1303-536
cPTT/CTS (central polypurine tract/central termination sequence)	L17-L18	2028-2151

PCMV IE (human cytomegalovirus immediate early promoter)	L18-L23	2185-2787
Reverse-1 primer binding site	L23	2787-2806
AmCyan1 fluorescent protein gene	L23-L29	2807-3493
Forward-1 primer binding site	L28	3426-3445
MCS (Multiple cloning site)	L29	3507-3559
EcoRI restriction site (3523-3528)	L29	3523-3528
BamHI restriction site	L29	3554-3559
STOP codons	L29	3568-3578
P _{PGK} (phosphoglycerate kinase promoter)	L29-L33	3583-4091
Puro ^R (Puromycin resistance gene)	L34-L38	4112-4711
WPRE (woodchuck posttranscriptional regulatory element)	L39-L43	4725-5316
3' LTR	L45-L50	5519-6155
pUC origin of replication (complementary)	L53-L59	6625-7298
Amp ^R (Ampicillin resistance gene; β -lactamase)(complementary)	L60-L68	7443-8439

Table S3. DNA sequence of pE2-Crimson prokaryotic expression plasmid. Functional regions are highlighted with different colours. Note the binding sites of Forward-2 (Line-3) and Reverse-2 (Line-8) primers.

agcgccaataacgcaaacgcctctccccgcgttgccgattcattaatgcagctggcacgacaggtttcccgactggaagcgggcagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccacagcgtttacactttatgcttcggcgtcgatgtgtgtggaattgtgagcggataacaatttcacacagggaacagcctgaccatgattacgccaaagcttgcatgctcaggtcgactctagaggatccccgggtaccggctgccaccatggatagcactgagaacgttcaagcccttcacgcttcaaggtgcacatggagggtccgtgaacggccacgagttcgagatcgagggcgtggcgagggaagccctacgagggcacccagaccgccaagctgcaagtacaaaggcgcccccgtcccttcgctgggacatcctgtccccagttctctacggctccaaggcgtacatcaagcaccgcgacatccccgactacacagcagctcttccccgagggttcaagtgaggcgctgatgaacttcgaggacggcggtgtgtgacgtgacccaggactcctccctgaggacggcaccctcatctacacgtgaagttcatcggtgaacttccctccgacggcccgtaalgagaagaagactctgggtgggagccctccactgagcgcaactacccccgcgacggcgtgtgaagggcgagaaccacatggcgctgaagctgaagggcgggccactacgtgtgtgagttcaagtcacatcatatggccaagaagcccgtaagctgccccggtaccactacgtggactacaagctgcacatcaccctccacaacgaggactacacgtgtgtggagcagtagcagcgcgccgaggcccgccaccactgttccagtagcgccgcgactctagaattccaactgagcgccgtcgtaccattaccaactgtgtgtgtcaaaaataataggcctactagtcggccgtacggcccttctcgtcgcgcttccgtgtgatgacgggtgaaacctgtacacatgcagctccgagacggtcacagcttctgtgaagcggtgcccggagcagacaagcccgtcaggcgcgctcagcgggtgttgccgggtgtcggggtgctggttaactatgcggcatcagagcagattgtactgagagtgaccatatcggtgtgaataccgcacagatgcgtgaaggagaaaataccgcacagcgccctaaaggcctcgtgatacgcctattttataggttaattgtcatgataataatggttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaaccctattgtttattttctaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttaataatattgaaaggaagagtatgagtattcaacatttccgtgtgccttattccctttttcgcgcattttgccttctgttttctcaccagaacgctgggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtggttatactgaactggtatcaacagcggtgaagatccttgagagtttgcggcgaagaacgttttccaatgatgacacttttaaagttctgctatgtggcggttattatccgtattgacggggcaagagcaactcggtcggcgcatacactattctcagaatgacttggtgagtactcaccagtcacagaaaagcatcttacgtaggcatgacagtaagagaattatcagtgctgccataacatgagtgataacactcgggccaacttactctgacaacgatcgaggagcgaaggagctaaccgctttttgacaacatggggatcatgtaactcgcttgatcgttgggaaccggaagtgaatgaagccatacacaacgacgagcgtgacaccacgatgctgtagcaatggcaacaacgttgcgcaactattaactggcgaacttactctagcttccggcaacaattaatagactggatggaggcgataaagttgaggaccacttctgcgtcggccctccggctggtgtttatgtctgataaatctggagccgggtgagcgtgggtctcggttatcattgcagcactggggccagatggtaagccctccgtatcgtatctacacgacggggagtcaggcaactatggatgaacgaataagacagatcgctgagataggtgctcactgattaaagcatttggttaactgtcagaccaagttactcatatactattagattgatttaaaactcatttttaatttaaaagatctaggtgaagatccttttgataatctcatgacaaaatcccttaacgtgagtttctgttccactgagcgtcagaccgctagaaaagatcaaaagatcttcttgagatccttttttctgcgcgtaatctgctgcttgcgaacaaaaaaaccacgctaccagcggtgtgtgttgcggatcaagagctaccaactcttttccgaaggttaactggctcagcagagcgagataccaataactgttcttctagtgtagccgttagtgccaccacttcaagaactctgtgacccgctacatacctcgtcgtgtaactctgttaccagtggtgtcgtccagtggtgcgataagctgtgttaccgggttgactcaagacgatgttaccggataaggcgacgggtcggtgaacgggggggttcgtgcacacagcccagcttgagcgaacgactacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgctccgaaggagaaaggcgacaggtatccggaagcgcgagggtcggaacaggagagcgacgagggagcttccagggggaacgcctggtatctttagtctgtcgggttgcacactctgacttgagcgtcgtattttgtgatgctcgtcagggggcgagcctatggaaaaacgccagcaacgcgcccttttaccggttctggccttttctgacatgttcttctcggttatccctgattctgtggataaccgtattaccgcttgagtgtgataccgctcgcgcgagccgaacgaccgagcgagcagtcagtgagcgaggaagcggaag

Functional DNA region	Line number	Base number
P _{lac} (lac promoter)	L1-L2	95-178
Ribosome binding site	L2	206-209
Start codon	L2	217-219
5' MCS (multiple cloning site)	L2-L3	234-281
Forward-2 primer binding site	L3	289-309
E2-Crimson fluorescent protein gene	L3-L8	289-966
Reverse-2 primer binding site	L8	946-966
3' MCS (multiple cloning site)	L8-L9	966-1065
Amp ^R (Ampicillin resistance gene; β -lactamase)	L13-L19	1511-2371
pUC origin of replication	L21-L26	2519-3161

Table S4. DNA sequence of pZsYellow prokaryotic expression plasmid. Functional regions are highlighted with different colours. Note the binding sites of Forward-3 (Line-3) and Reverse-3 (Line-8) primers.

agcgccaatacgcacaaacgcctctccccgcgcttgccgattcattaatgcagctggcagcacaggtttcccgactggaagcgggcagtgagcgcaacgcaattaatgtgagttagctcact
cattaggcagccaggtttacactttatgcttccggctcgtatgttgggaattgtgagcggataacaatttcacacagggaacagctatgacatgattacgccaaagcttgcatgcctgcaggt
cgactctagaggatccccgggtaccggctgccaccatggctcattcaaagcacgggtctaaaagaagaatgacaatgaaataccacatggaaggggtgcgtcaacggacataaatttggatcac
ggcggaaggtcattggatccgttcaaagggaaacagactattaatctgtgtgtgatcgaagggggaccattgccattttccgaagacatattgtcagctggcttaagtacggagacaggtttt
cactgaatatcctcaagacatagtagactatttcaagaactcgtgtcctgctggatatacatggggcaggtctttctcttggagatggagcagctcgcataatgtagatataacagtgagtg
tcaaagaaaactgcatttatcataagagcatatttaattggagtgaaatttctctgctgatggacctgtgatgaaaaagatgacaactaactgggaagcatcctgcgagaagatcatgccagtaccta
agcaggggatactgaaaggggatgtctccatgtacctccttctgaaggtggtggcggttaccgggtgccagttcgacacagtttacaagcaaaagctgtgccaagtaagatgccggagtgga
cttcatccagcataagctcctcgtgaagaccgcagcgtactaagaatcagaagtggcagctgacagagcatgctattgcaatccctctgccttggcctgaagcggccgcgactctagaattcc
aactgagcgcgggtcgtaccattaccaacttgcctggtgtcaaaaaataataggcctactagtcggccgtacgggccccttctcgtcgcgctttcgggtgatcgggtgaaaacctctgacacatgc
agctcccggagacgggtcacagcttgcgtgaagcggatgcggggagcagacaagcccgtcagggcgctcagcgggtgttggcgggtgtcggggctggcttaactatgcggcatcagagca
gattgtactgagagtgacacatagcgggtgtgaaataccgcacagatgcgtaaggagaaaaataccgcacagcggccttaaggcctcgtgatccctattttataggttaattgtcatgataa
taatggtttcttagacgtcaggtggcacttttccgggaaatgtgcgggaacccctatttcttatttttcaataacattcaaatatgtatccgctcatgacaataacctgataaattgctcaataat
attgaaaaaggaagagtatgagtattcaacattccgtgtcgccttattcccttttttgcgcgattttgccttctgttttgcctaccagaacagctgggtgaaagtaaaagatgtgaagatcagttg
ggtgcagagtggtggtatcatcgaactggatctcaacacgggtaagatccttgagagtttgcggcggaagacgtttccaatgatgacacttttaaagttctgctatgtggcgcggtattatccc
tattgacggcggaagagcaactcggctcgcgcacatactattctcagaatgacttgggtgagtactcaccagtcacagaaaaagatcttacggatggcatgacagtaagagaattatgcagtg
ctgcataacatgagtgataaactgcggcaacttactctgacaacgatcggaggaccgaaggagtaaccgctttttgcacaacatgggggatcatgtaactgccttgatcgttgggaac
cggagctgaatgaagccataccaacacgacgagcgtgacaccagatgcctgtagcaatggcaacaacgttgcgcaactattaactggcgaactacttacttagcttcccgcgaacaattaata
gactggatggaggcggataaagttgcaggaccacttctgcgtcggccttccggctggtgttattgtctgataaatctggagccggtgagcgtgggtctcgcggatcattgcagcactggg
gccagatggtaagccctcccgtatcgtatctacacgacggggagtcaggcaactatggatgaacgaatagacagatcgcctgagataggtgcctcactgattaagcattggttaactgtcag
accaagtttactcatatatacttttagattgatttaaaactcatttttaatttaaaaggatctaggtgaagatccttttgataatctcatgacaaaaatcccttaacgtgagtttcttccactgagcgtca
gaccccgtagaaaagatcaaagatcttcttgagatccttttttctgcgcgtaattctgctgttgcgaacaaaaaaaccacgcctaccagcgggtgttgttgcggatcaagagctaccaactctt
ttccgaaggttaactggcttcagcagagcgcagataccaataactgttctttagttagcgcgtatgttaggcccaccacttcaagaactctgtagaccgcctacatactcgtctgctaatcctgtta
ccagtggctgctgccagtggcgataagtcgtgtcttaccgggttgactcaagacgatagttaccggataagcgcgagcgggtcgggtgaacgggggggttcgtgcacacagccagccttggga
gcgaacgacctacaccaactgagatacctacagcgtgagctatgagaagcgccacgcttcccgaaggagaaaggcgagcggatccggttaagcggcaggggtcggaacaggagagc
gcacgagggagcttccagggggaacgccttggtatctttagtctcgtcgggttccgacactctgacttgagcgtcgtatgttggatgctcgtcagggggcgagcctatggaaaaacgcc
agcaacgcggccttttaccggttcttgcccttttctggtgcttttctcatatgttcttctcgttatccctgattctgtggataaccgtattaccgctttagtgagctgataccgctcgcgcgagc
cgaacgaccgagcgcagcagtgagcaggaagcggaag

Functional DNA region	Line number	Base number
Plac (lac promoter)	L1-L2	95-178
Ribosome binding site	L2	206-209
Start codon	L2	217-219
5' MCS (multiple cloning site)	L2-L3	234-292
Forward-3 primer binding site	L3	289-309
ZsYellow fluorescent protein gene	L3-L8	289-984
Reverse-3 primer binding site	L8	964-984
3' MCS (multiple cloning site)	L8-L9	986-1085
Amp ^R (Ampicillin resistance gene; β -lactamase)	L13-L19	1531-2391
pUC origin of replication	L21-L26	2539-3181

Table S5. DNA alignment of the theorised (Query) and engineered (Sbjct) sequences of pLVX-E2.Crimson-C1 plasmid. A forward primer (5' gtacggtgggaggtctatat 3') was used for the sequencing.

Query	2721	CGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGACTC	2780
Sbjct	9	CGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGACTC	68
Query	2781	TACTAGAGGATCTACCGGTCGCCACCCTCGAGATGGATAGCACTGAGAACGTCATCAAGC	2840
Sbjct	69	TACTAGAGGATCTACCGGTCGCCACCCTCGAGATGGATAGCACTGAGAACGTCATCAAGC	128
Query	2841	CCTTCATGCGCTTCAAGGTGCACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCG	2900
Sbjct	129	CCTTCATGCGCTTCAAGGTGCACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCG	188
Query	2901	AGGGCGTGGGCGAGGGCAAGCCCTACGAGGGCACCAGACCGCCAAGCTGCAAGTGACCA	2960
Sbjct	189	AGGGCGTGGGCGAGGGCAAGCCCTACGAGGGCACCAGACCGCCAAGCTGCAAGTGACCA	248
Query	2961	AGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCAGTTCTTCTACGGCTCCA	3020
Sbjct	249	AGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCAGTTCTTCTACGGCTCCA	308
Query	3021	AGGCGTACATCAAGCACCCCGCCGACATCCCCGACTACCTCAAGCAGTCCTTCCCCGAGG	3080
Sbjct	309	AGGCGTACATCAAGCACCCCGCCGACATCCCCGACTACCTCAAGCAGTCCTTCCCCGAGG	368
Query	3081	GCTTCAAGTGGGAGCGCGTGATGAACCTTCGAGGACGGCGGCGTGGTGACCGTGACCCAGG	3140
Sbjct	369	GCTTCAAGTGGGAGCGCGTGATGAACCTTCGAGGACGGCGGCGTGGTGACCGTGACCCAGG	428
Query	3141	ACTCCTCCCTGCAGGACGGCACCCTCATCTACCACGTGAAGTTCATCGGCGTGAACTTCC	3200
Sbjct	429	ACTCCTCCCTGCAGGACGGCACCCTCATCTACCACGTGAAGTTCATCGGCGTGAACTTCC	488
Query	3201	CCTCCGACGGCCCCGTAATGCAGAAGAAGACTCTGGGCTGGGAGCCCTCCACTGAGCGCA	3260
Sbjct	489	CCTCCGACGGCCCCGTAATGCAGAAGAAGACTCTGGGCTGGGAGCCCTCCACTGAGCGCA	548
Query	3261	ACTACCCCCGCGACGGCGTGCTGAAGGGCGAGAACCACATGGCGCTGAAGCTGAAGGGCG	3320
Sbjct	549	ACTACCCCCGCGACGGCGTGCTGAAGGGCGAGAACCACATGGCGCTGAAGCTGAAGGGCG	608
Query	3321	GCGGCCACTACCTGTGTGAGTTCAAGTCCATCTACATGGCCAAGAAGCCCGTGAAGCTGC	3380
Sbjct	609	GCGGCCACTACCTGTGTGAGTTCAAGTCCATCTACATGGCCAAGAAGCCCGTGAAGCTGC	668
Query	3381	CCGGCTACCACTACGTGGACTACAAGCTCGACATCACCTCCCACAACGAGGACTACACCG	3440
Sbjct	669	CCGGCTACCACTACGTGGACTACAAGCTCGACATCACCTCCCACAACGAGGACTACACCG	728
Query	3441	TGGTGGAGCAGTACGAGCGCGCCGAGGCCCGCCACCACCTGTTCCAGTAGGAATTCTG-C	3499
Sbjct	729	TGGTGGAGCAGTACGAGCGCGCCGAGGCCCGCCACCACCTGTTCCAGTAGGAATTCTGCC	788
Query	3500	AGTCGACGGTACCGCGGGCCCGGATCCACCGGA-TCTAGATAACTGATCATAATTCTAC	3558
Sbjct	789	AGTCGACGGTACCGCGGGCCCGGATCCACCGGATTCTAGATAACTGATCATAATT-TAG	847
Query	3559	CGGGTAGGGGAGGCGCTTTTCCC-A-AGGCAGTCTGGAGCAT-GCGCTTTAGCAGCCCCG	3615
Sbjct	848	CGGGAAGGGGAGGCGCTTTTCCCCAGAGGCAGTCTGGAGCGTTGTACTTACCCACCCCT	907
Query	3616	CTGGGCACTTGGCG	3629
Sbjct	908	CGGGGCACCTGGCG	921

Functional DNA region	Base number (on Query seq.)
pLVX backbone (flanking 5' end of E2.Crimson gene)	← 2721-2806
XhoI restriction site	2807-2812
Start codon	2813-2815
E2.Crimson fluorescent protein gene	2813-3490
Stop codon	3488-3490
EcoRI restriction site	3491-3496
pLVX backbone (flanking 3' end of E.2 Crimson gene)	3497-3629 →
Triple Stop codons (located in the backbone of pLVX plasmid)	3536-3546

Table S6. DNA alignment of the theorised (Query) and engineered (Sbjct) sequences of pLVX-E2.Crimson-C1 plasmid. A reverse primer (5' cagactgccttgggaaaa 3') was used for the sequencing.

Query	2944	CAAGCTGCAAGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGG-ACATCCTGTCCCCC	3002
Sbjct	613	CAAGCTGCTAGTGACCAAGTGCGGCCCCCTGCCCTTCGCCTGGGTACATCCTGTCCCCC	554
Query	3003	AGTTCTTCTACGGCTCCAAGGCGTACATCAAGCACCCCGCCGACATCCCCGACTACCTCA	3062
Sbjct	553	AGTT-TTCTACGGCTCCAAGGCGTACATCAAGCACCCCGCCGACATCCCCGACTACCTCA	495
Query	3063	AGCAGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAAC TTCGAGGACGGCGGCG	3122
Sbjct	494	AGCAGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAAC TTCGAGGACGGCGGCG	435
Query	3123	TGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCACCCCTCATCTACCACGTGAAGT	3182
Sbjct	434	TGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCACCCCTCATCTACCACGTGAAGT	375
Query	3183	TCATCGGCGTGAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACTCTGGGCTGGG	3242
Sbjct	374	TCATCGGCGTGAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACTCTGGGCTGGG	315
Query	3243	AGCCCTCCACTGAGCGCAACTACCCCGCGACGGCGTGCTGAAGGGCGAGAACCACATGG	3302
Sbjct	314	AGCCCTCCACTGAGCGCAACTACCCCGCGACGGCGTGCTGAAGGGCGAGAACCACATGG	255
Query	3303	CGCTGAAGCTGAAGGGCGGCGGCCACTACCTGTGTGAGTTCAAGTCCATCTACATGGCCA	3362
Sbjct	254	CGCTGAAGCTGAAGGGCGGCGGCCACTACCTGTGTGAGTTCAAGTCCATCTACATGGCCA	195
Query	3363	AGAAGCCCGTGAAGCTGCCCGGCTACCACTACGTGGACTACAAGCTCGACATCACCTCCC	3422
Sbjct	194	AGAAGCCCGTGAAGCTGCCCGGCTACCACTACGTGGACTACAAGCTCGACATCACCTCCC	135
Query	3423	ACAACGAGGACTACACCGTGGTGGAGCAGTACGAGCGCGCCGAGGCCCGCCACCACCTGT	3482
Sbjct	134	ACAACGAGGACTACACCGTGGTGGAGCAGTACGAGCGCGCCGAGGCCCGCCACCACCTGT	75
Query	3483	TCCAGTAGGAATTCTGCAGTCGACGGTACCGCGGGCCCGGGATCCACCGGATCTAGATAA	3542
Sbjct	74	TCCAGTAGGAATTCTGCAGTCGACGGTACCGCGGGCCCGGGATCCACCGGATCTAGATAA	15
Query	3543	CTGATCATA 3551	
Sbjct	14	CTGATCATA 6	

Functional DNA region	Base number (on Query seq.)
E2.Crimson fluorescent protein gene (covering 132-678 bases)	← 2944-3490
Stop codon	3488-3490
EcoRI restriction site	3491-3496
pLVX backbone (flanking 3' end of E.2 Crimson gene)	3497-3551→
Triple Stop codons (located in the backbone of pLVX plasmid)	3536-3546

Table S7. Primary glioblastoma cell lines that were successfully infected with lentiviral particles. The protocol in Results Section 3.6 “Preparation and purification of lentiviral particles” was used to prepare the lentiviral particles.

	Cell line [1,2]	Reference no.		Cell line	Reference no.		Cell line	Reference no.
1	BAH1	QIMR-B001	5	MMK1	QIMR-B001	9	RN1	QIMR-B001
2	FPW1	QIMR-B001	6	MN1	QIMR-B001	10	SB2b	QIMR-B001
3	HW1	QIMR-B001	7	PB1	QIMR-B001	11	SJH1	QIMR-B001
4	JK2	QIMR-B001	8	RK11	QIMR-B001	12	WK1	QIMR-B001




Figure S1. Outline of High-Fidelity Amplification-Restriction-Ligation strategy.




Figure S2. Heat shock technique is used to transform the competent bacteria with newly engineered pLVX-E2-Crimson-C1 lentiviral constructs. A, Efficiency of bacterial colony formation is assessed by inoculating different volumes of heat-shocked bacteria. B, Quantification of bacteria clones in A after 16 hours of incubation at 37°C.

References

1. Stringer, B.W.; Day, B.W.; D'Souza, R.C.J.; Jamieson, P.R.; Ensbey, K.S.; Bruce, Z.C.; Lim, Y.C.; Goasdoue, K.; Offenhauser, C.; Akgul, S.; et al. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. *Sci Rep* **2019**, *9*, 4902, doi:10.1038/s41598-019-41277-z.
2. QIMR, B.M.R.I. QCell. Available online: <https://www.qimrberghofer.edu.au/commercial-collaborations/partner-with-us/qcell/> (accessed on 14/02/2022).